Company / SG&A per Share
Rein Therapeutics, Inc. SG&A per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.64
FY2025
5-year range
$0.21 / $2.32
FY2021-FY2025
Trend
-72.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A per Share has fluctuated over the past 9 years, ranging from $0.21 in FY2021 to $11.70 in FY2017.
Based on SEC 10-K filings.
0.64 in FY2025 with a 5-year CAGR of +7.7%.
Improved from $2.13 to $0.64 over the past 2 years.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -32.9%
- 5-Year CAGR
- +7.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, sg&a per share decreased 72.5% year-over-year.
- Peak sg&a per share was recorded in FY2017.
- Lowest sg&a per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.64 | -72.5% |
| FY2024 | $2.32 | +9.1% |
| FY2023 | $2.13 | +0.6% |
| FY2022 | $2.12 | +894.9% |
| FY2021 | $0.21 | -51.8% |
| FY2020 | $0.44 | -51.5% |
| FY2019 | $0.91 | +53.2% |
| FY2018 | $0.60 | -94.9% |
| FY2017 | $11.70 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026